By Chuck Mikolajczak
(Reuters) - U.S. stocks rose on Friday, lifted by results from NIKE (NKE.NY)and another climb in biotechs, as investors assessed the impact of a stronger dollar on corporate earnings.
Dow component Nike
"There is a tug-of-war going on between current valuations in our market and a lot of bad news being priced into a strong dollar, with no good news being priced into a strong dollar," said Art Hogan, chief market strategist at Wunderlich Securities in New York.
"We are taking the multinationals out to the woodshed and not moving consumer names higher."
Biotechs were on track for their eighth straight advance, powered by a 6.6 percent climb in Biogen Idec
The Dow Jones industrial average <.DJI> rose 140 points, or 0.78 percent, to 18,099.03, the S&P 500 <.SPX> gained 14.17 points, or 0.68 percent, to 2,103.44 and the Nasdaq Composite <.IXIC> added 34.90 points, or 0.7 percent, to 5,027.28.
The market may see heightened volatility heading into the close as a result of quadruple witching - the expiration of stock options, index options, index futures and single-stock futures.
Olive Garden owner Darden Restaurants
But Tiffany & Co.
The dollar <.DXY> was off 1.2 percent against a basket of major currencies and was on track for its first weekly decline in five. [USD/]
Simon Property Group
Advancing issues outnumbered declining ones on the NYSE by 2,268 to 482, for a 4.71-to-1 ratio; on the Nasdaq, 1,682 issues rose and 642 fell for a 2.62-to-1 ratio favoring advancers.
The benchmark S&P 500 index was posting 52 new 52-week highs and no new lows; the Nasdaq Composite was recording 130 new highs and 7 new lows.
(Editing by Bernadette Baum)